3.2 billion market change? Fourth batch collection, Pfizer "exclusive three yuan"?

Pfizer, Cosmos, the world's largest pharmaceutical company, has been hit by a volume-buying policy that has made the future even more uncertain.
According to the data combed by the author, each round of volume procurement is closely related to Pfizer, anecdoary talk, a "national harvest is tailored for Pfizer", or has become a reality.
't you? I don't know, but the company with the biggest impact must be Pfizer, not one of them.
The first three rounds of collection, the first three batches of Pfizer collection Pfizer (including later Puqiang) for the centralized procurement of drugs contributed to 10 varieties, involving 10 billion varieties of atovastatin calcium, benzodiamin chloride, but also just listed new drug Tofatib.
Three collections involve Pfizer products in the field of treatment, cardiovascular, anti-infection, urinary, analgesic, spiritual, rheumic immunity and anticoagulant, basically involving the vast majority of Pfizer therapeutic areas, most of these products are in the field of head products, such as Lipto, Live Hi, Celexi and other well-known brands.
The first three national collections of Pfizer involved varieties: the first batch of national collection varieties: atovastatin calcium (Lipto), benzodiamin chloride (Live Hi) Second batch: Achimycin (Chishumi), fluconazole (Da Fukang) third batch: Apisaban (Elato), Sidinafi (Van Aico/Viago), Leigh The first three concentrated purchases of Nyazole tablets (Svo), Celexib (Serepulchre), Schaequoia (Zulofu), and Tofatib (Shangjie) have had a strong impact on Pfizer: multiple architectural changes, from Pfizer to Pfizer, Pfizer merged with Mylan to form a new company, and the company is now Pfizer, which sells Mylan and Pfizer patent expired drugs.
Such rapid changes accelerate the change of Pfizer executives, promote Pfizer's rapid development of the "three Wu" era, the general manager of the five major pharmaceutical business units left at the same time, brain drain, the impact on Pfizer can not be underestimated.
Pfizer is no longer number one globally or in China, which has been overtaken by Novarma and Roche, and China has been replaced by AstraZeneta.
latest news, Pfizer began to lay off workers, middle managers began, inflammatory immune lay off 5 regional managers, anti-infection lay off 11 regional managers, Pfizer middle-level competition will begin on the 20th of this month.
middle-of-the-year downsizing will start with layoffs of regional managers and sales representatives, a phase in which headhunters are frantically contacting Pfizer representatives, after all, Pfizer's strong sales in the industry are still evident.
these operations should serve two purposes, reducing Pfizer's operating costs, increasing profits, and accounting for shareholders, and, in part, to transform Pfizer's business model.
based on strong genes and a culture of excellence, a return to the Chinese market in the future is not out of the way.
the fourth batch of collection, involving 3.2 billion days ago, the fourth batch of drug collection list announced, of which Parrxib sodium and voliconazole belong to Pfizer Biopharmaceuticals, Prieban belongs to Pfizer product line.
will once again accelerate the transformation of Pfizer's business model: 1, Tofatib (Shangjie) three batches of finalists, the fourth batch of Parrxib sodium shortlisted, Pfizer's inflammatory immunology product line basically no business support products, the future of the product line is worth considering.
, according to pharmaceutical data, the injection of Parexib sodium for the 2019 edition of the National Health Insurance Directory varieties, 2019 China's sales of 1,996 million yuan.
koren injection with Parrisheb sodium for the domestic first imitation market.
variety is a selective cyclooxidase-2 (COX-2) inhibitor, mainly used for short-term treatment of pain after surgery.
has been recommended by many authoritative guidelines at home and abroad for general surgery, gynecology, orthopaedics, oral medicine and other departments.
2, Pfizer three major anti-infective heavy oral preparations all into the collection, Da Fukang, Svo and Viven tablets, if the conditions are ripe, anti-infective injections are not possible.
3, we think that only large varieties will be collected, Pfizer Pribarin market capacity of 200 million, but also into the collection, it can be seen that the collection and sales have nothing to do.
doesn't seem so optimistic around the world, and on May 24, 2019, Pfizer announced the final results of a Phase 3 clinical trial evaluating the effectiveness and safety of LYRICA® for the treatment of primary systemic prosthetic seizures, but did not reach its primary clinical endpoint, according to Pharmaceutical Intelligence.com.
does this collection have to do with it? There is a saying that large varieties into the collection, saving health insurance funds, there is another way of saying that generic drugs into the collection, accelerate the patent cliff, there is a saying, there is no reason, the conditions are mature to be collected, irrelevant sales and patent or not.
If this is the case, from the position of pharmaceutical companies, China's pharmaceutical companies have just begun the winter, this should be the starting point, the cold will continue, enterprises need to winter, whether the medical people from the mentality, skills and planning ability to prepare to withstand the cold for decades.
Pfizer sales strength, decided its response to the collection strategy of the first three batch of catalog products Pfizer shortlisted ten, Pfizer is also the only large number of finalists, but no product winning the enterprise, collection can still be sold.
the status quo is very worthy of reference, whether it is also of reference value to other enterprises.
1, Pfizer sales, stable and systematic.
No company sales force such as Pfizer version of the stable, and Pfizer senior management are mostly Pfizer sales representatives, anti-infection, tumor, vaccine general managers are through a hundred battles, deep understanding of Pfizer's strong sales.
, and even more so for regional directors and regional managers, Pfizer loves Pfizer more than outsiders.
2, Pfizer products, forward-looking and high-quality.
In the age when oncology treatment was not yet emerging, Pfizer's product line was laid out in more than 10 locations, and there was no shortage of first-share products in each area, such as blood lipids, lipids, lipids; bucking, live joy; anti-infection, Shupu deep; Vivan; analgesics, celery, Tyne; urology, Van Aico, and so on.
3, Pfizer culture, strong and stable.
Pfizer advocates results-oriented, controlling the changing world.
and management, who grew up at Pfizer's grassroots level, embrace this culture and pass it on from generation to generation as a code of conduct that runs through daily customer visits.
's not a Pfizer ad post, but Pfizer's long-standing dominance of the world's pharmaceutical companies is probably a very important reason.